BlackBerry Shares Rise as Q2 Earnings, Revenue Beat Estimates 
US Backs Musk in Fight Against EU’s €120 Million X Fine 
Almonty Industries Shares Jump 8% After Stifel Sets $25 Target 
BMW 2028 Margin Target Could Fall Below Consensus, UBS Says 
OpenAI Agent Breaches Australia Medicare Data Portal 
Novo Nordisk Strikes €1.17 Billion Nanexa Drug Delivery Deal 
Jeff Bezos Invests $32 Billion in Blue Origin as Space Firm Targets Major Growth 
SoftBank Shares Fall as Oracle Flags Stargate Data Center Delay Risk 
SMBC Eyes 20% VPBank Stake in Vietnam Expansion 
Former OpenAI Data Center Chief Chris Malone Joins Nvidia 
DaVoice Sues Perplexity AI Over Trade Secrets 
Dubai’s connectivity remains strong in an uncertain world 
US Appeals Court Upholds Anthropic AI Supply Chain Ban 
Airbus Finds A321neo Fuselage Quality Issue 
Oracle Shares Fall as New Mexico AI Data Center Faces Power Delays 
SpaceXAI to Double Nvidia Chips at Colossus 2 by Year-End 
Add as a preferred source on Google
A US district court upheld the validity of Novartis' patent for its top-selling multiple sclerosis (MS) drug Gilenya, rejecting a lawsuit from generic drug maker HEC.
Gilenya is the Swiss drugmaker's No. 2 revenue generator at $738 million in the second quarter.
HEC had sought approval to make a generic copy of Gilenya before the expiration of Novartis' patent with the US Food and Drug Administration (FDA).
The Swiss drugmaker said it continued the injunction against the marketing and sale of Gilenya and other generics granted to it in June 2019.
The FDA approved three generic versions of the Novartis MS treatment in December.
Novartis had settlement agreements with other manufacturers to allow them to launch generic versions of Gilenya before the patent expires in 2027.
